Sign in or create an account to add this stock to your watchlist.
About Alkermes (NASDAQ:ALKS)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000
Debt
Debt-to-Equity Ratio0.24
Current Ratio2.83
Quick Ratio2.52
Price-To-Earnings
Trailing P/E Ratio-123.35
Forward P/E Ratio-69.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$903.37 million
Price / Sales7.83
Cash Flow$0.2761 per share
Price / Cash165.33
Book Value$7.46 per share
Price / Book6.12
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-157,940,000.00
Net Margins-16.18%
Return on Equity-3.13%
Return on Assets-2.12%
Miscellaneous
Employees2,000
Outstanding Shares155,040,000
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes Plc (NASDAQ:ALKS) issued its earnings results on Thursday, April, 26th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.02. The business earned $225.20 million during the quarter, compared to analyst estimates of $219.51 million. Alkermes had a negative net margin of 16.18% and a negative return on equity of 3.13%. The company's revenue for the quarter was up 17.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.18) EPS. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
What price target have analysts set for ALKS?
12 equities research analysts have issued 1 year target prices for Alkermes' shares. Their forecasts range from $45.00 to $81.00. On average, they expect Alkermes' stock price to reach $59.75 in the next twelve months. View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes' Vivitrol and Aristada are primary growth drivers. 2018 is expected to be a transformative year for Alkermes’ development pipeline, with key events being- the phase III data readout for ALKS 3831 in schizophrenia, submission of the BIIB098 (ALKS 8700) NDA and phase I data read-out for ALKS 4230.In April 2018, the FDA accepted for review the new drug application (NDA) for ALKS 5461 for the treatment of major depressive disorder (“MDD”). The FDA had initially issued a Refusal to File letter on Mar 30 for the candidate stating that the NDA did not have enough evidence for the oral medication to work. The company also expects to expand its field sales team by about 200 sales representatives in mid 2018 as it prepares for the potential launch of ALKS 5461 in early 2019. However, Alkermes is highly dependent on manufacturing and/or royalty revenues on sales of products that are commercialized by the company's partners" (4/20/2018)
- 2. Cantor Fitzgerald analysts commented, "FDA response looks like someone may not have been listening. The nature of the FDA response to ALKS stands in stark contrast to a comment by the CEO on the 2Q17 results conference call, Earlier this week, we passed a major milestone with the outcome of our pre-NDA meeting with the FDA, which resulted in an agreement on our NDA submission content and timing." We generally take with a grain of salt any management comments that FDA meetings went well" or were productive" but we believe investors may have been led to believe that the FDA viewed the ALKS 5461 data as potentially adequate for approval. That the FDA evidently has asked for additional clinical studies strongly calls into question such an assumption, in our opinion." (4/2/2018)
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF), Nektar Therapeutics (NKTR), Ono Pharmaceutical (OPHLF), Merck Group (MKGAF), Genmab (GNMSF), Perrigo (PRGO), BeiGene (BGNE), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY) and Valeant Pharmaceuticals Intl (VRX).
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 56)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 81)
- Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 51)
- Ms. Kathryn L. Biberstein, Chief Admin. Officer, Chief Compliance Officer, Chief Risk Officer & Exec. VP (Age 59)
- Dr. Elliot W. Ehrich, Exec. VP of R&D (Age 59)
Has Alkermes been receiving favorable news coverage?
Media stories about ALKS stock have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alkermes earned a media sentiment score of 0.06 on Accern's scale. They also gave media stories about the company an impact score of 46.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Alkermes' major shareholders?
Alkermes' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.71%), Woodford Investment Management Ltd (3.40%), Thornburg Investment Management Inc. (2.02%), Franklin Resources Inc. (1.94%), Northern Trust Corp (0.55%) and Frontier Capital Management Co. LLC (0.46%). Company insiders that own Alkermes stock include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes.
Which major investors are selling Alkermes stock?
ALKS stock was sold by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, BlackRock Inc., Thornburg Investment Management Inc., Franklin Resources Inc., Sei Investments Co., Amundi Pioneer Asset Management Inc., Swiss National Bank and State of Wisconsin Investment Board. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops and Shane Cooke. View Insider Buying and Selling for Alkermes.
Which major investors are buying Alkermes stock?
ALKS stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Seven Eight Capital LP, Frontier Capital Management Co. LLC, Schwab Charles Investment Management Inc., Tamarack Advisers LP, Royal Bank of Canada, GW&K Investment Management LLC and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Alkermes.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $45.64.
How big of a company is Alkermes?
Alkermes has a market capitalization of $7.07 billion and generates $903.37 million in revenue each year. The company earns $-157,940,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Alkermes employs 2,000 workers across the globe.
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]
MarketBeat Community Rating for Alkermes (ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alkermes (NASDAQ:ALKS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Alkermes in the last 12 months. Their average twelve-month price target is $59.75, suggesting that the stock has a possible upside of 30.92%. The high price target for ALKS is $81.00 and the low price target for ALKS is $45.00. There are currently 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Hold | Hold | Hold |
| Consensus Rating Score: | 2.50 | 2.36 | 2.36 | 2.45 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $59.75 | $60.6364 | $64.00 | $63.5455 |
| Price Target Upside: | 30.92% upside | 37.31% upside | 13.17% upside | 27.47% upside |
Alkermes (NASDAQ:ALKS) Consensus Price Target History
Alkermes (NASDAQ:ALKS) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Alkermes (NASDAQ:ALKS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Alkermes (NASDAQ ALKS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.34%
Alkermes (NASDAQ ALKS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Michael J Landine | SVP | Sell | 20,000 | $46.14 | $922,800.00 | 192,644 |  |
| 5/15/2018 | Richard F Pops | CEO | Sell | 50,000 | $46.38 | $2,319,000.00 | 716,352 | |
| 5/8/2018 | Richard F Pops | CEO | Sell | 50,000 | $44.32 | $2,216,000.00 | 716,352 | |
| 5/1/2018 | Richard F Pops | Director | Sell | 50,000 | $44.02 | $2,201,000.00 | 716,352 | |
| 4/2/2018 | Paul J Mitchell | Director | Sell | 1,000 | $46.75 | $46,750.00 | 8,000 | |
| 3/1/2018 | Paul J Mitchell | Director | Sell | 1,000 | $57.04 | $57,040.00 | 9,000 | |
| 2/16/2018 | Mark Stejbach | SVP | Sell | 10,880 | $70.50 | $767,040.00 | 54,893 | |
| 2/2/2018 | Shane Cooke | Insider | Sell | 72,793 | $60.55 | $4,407,616.15 | 147,501 | |
| 2/1/2018 | Paul J Mitchell | Director | Sell | 1,000 | $56.77 | $56,770.00 | 9,000 | |
| 1/29/2018 | Shane Cooke | Insider | Sell | 3,300 | $60.00 | $198,000.00 | 76,408 | |
| 1/26/2018 | Shane Cooke | Insider | Sell | 1,700 | $60.02 | $102,034.00 | 76,408 | |
| 1/11/2018 | Shane Cooke | Insider | Sell | 6,207 | $60.22 | $373,785.54 | 80,915 | |
| 1/2/2018 | Paul J Mitchell | Director | Sell | 1,000 | $54.99 | $54,990.00 | 9,000 | |
| 12/29/2017 | Iain Michael Brown | SVP | Sell | 10,652 | $54.81 | $583,836.12 | | |
| 12/29/2017 | Iain Michael Brown | CAO | Sell | 10,652 | $54.81 | $583,836.12 | 16,943 | |
| 12/20/2017 | Laurie Keating | SVP | Sell | 6,249 | $121.20 | $757,378.80 | | |
| 12/1/2017 | Paul J Mitchell | Director | Sell | 1,000 | $51.98 | $51,980.00 | 9,000 | |
| 11/29/2017 | James M Frates | SVP | Sell | 20,932 | $50.51 | $1,057,275.32 | 164,971 | |
| 11/8/2017 | James M. Frates | SVP | Sell | 20,932 | $47.58 | $995,944.56 | | |
| 11/2/2017 | Richard F Pops | Director | Sell | 50,000 | $48.87 | $2,443,500.00 | | |
| 11/1/2017 | Michael J Landine | SVP | Sell | 15,000 | $48.71 | $730,650.00 | 178,693 | |
| 10/2/2017 | Paul J Mitchell | Director | Sell | 1,500 | $50.64 | $75,960.00 | | |
| 9/11/2017 | Kathryn L Biberstein | CAO | Sell | 13,566 | $51.29 | $695,800.14 | 70,455 | |
| 9/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $50.77 | $76,155.00 | 9,500 | |
| 8/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $54.91 | $82,365.00 | 9,500 | |
| 7/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $58.11 | $87,165.00 | 9,500 | |
| 6/8/2017 | Shane Cooke | Insider | Sell | 10,000 | $60.33 | $603,300.00 | 84,708 | |
| 6/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $57.49 | $86,235.00 | 9,500 | |
| 5/24/2017 | Richard F Pops | Director | Sell | 25,000 | $57.42 | $1,435,500.00 | 649,137 | |
| 5/18/2017 | Michael J Landine | SVP | Sell | 10,000 | $57.23 | $572,300.00 | 167,370 | |
| 5/17/2017 | Richard F Pops | Director | Sell | 50,000 | $58.19 | $2,909,500.00 | 680,406 | |
| 5/11/2017 | Michael J Landine | SVP | Sell | 10,000 | $57.01 | $570,100.00 | 172,370 | |
| 5/10/2017 | Richard F Pops | Director | Sell | 25,000 | $57.29 | $1,432,250.00 | 655,406 | |
| 5/4/2017 | Shane Cooke | Insider | Sell | 6,500 | $60.05 | $390,325.00 | 78,448 | |
| 4/17/2017 | Elliot Ehrich | CMO | Sell | 10,000 | $56.60 | $566,000.00 | 65,071 | |
| 4/3/2017 | Kathryn L Biberstein | CAO | Sell | 15,000 | $57.68 | $865,200.00 | 69,904 | |
| 4/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $58.31 | $87,465.00 | 9,500 | |
| 3/29/2017 | Shane Cooke | Insider | Sell | 2,070 | $60.00 | $124,200.00 | 72,148 | |
| 3/23/2017 | Shane Cooke | Insider | Sell | 6,030 | $60.01 | $361,860.30 | 74,948 | |
| 3/21/2017 | Shane Cooke | Insider | Sell | 1,900 | $60.09 | $114,171.00 | 72,048 | |
| 3/20/2017 | Shane Cooke | Insider | Sell | 300 | $60.00 | $18,000.00 | 72,048 | |
| 3/15/2017 | Elliot Ehrich | CMO | Sell | 11,000 | $56.74 | $624,140.00 | 66,071 | |
| 3/7/2017 | James M Frates | SVP | Sell | 25,000 | $59.08 | $1,477,000.00 | 144,053 | |
| 3/2/2017 | Robert A Breyer | Director | Sell | 4,000 | $60.00 | $240,000.00 | 7,156 | |
| 3/2/2017 | Shane Cooke | Insider | Sell | 20,000 | $60.00 | $1,200,000.00 | 73,068 | |
| 3/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $57.06 | $85,590.00 | 9,500 | |
| 2/16/2017 | Elliot Ehrich | CMO | Sell | 11,000 | $56.68 | $623,480.00 | 49,657 | |
| 2/1/2017 | Paul J Mitchell | Director | Sell | 1,500 | $54.45 | $81,675.00 | 9,500 | |
| 1/17/2017 | Elliot Ehrich | CMO | Sell | 11,983 | $54.32 | $650,916.56 | 62,640 | |
| 1/9/2017 | Mark Stejbach | SVP | Sell | 547 | $60.27 | $32,967.69 | 34,662 | |
| 1/9/2017 | Shane Cooke | Insider | Sell | 550 | $60.27 | $33,148.50 | 64,494 | |
| 1/6/2017 | Elliot Ehrich | CMO | Sell | 10,000 | $59.44 | $594,400.00 | 60,140 | |
| 1/6/2017 | Mark Stejbach | SVP | Sell | 9,453 | $60.05 | $567,652.65 | 36,615 | |
| 1/6/2017 | Shane Cooke | Insider | Sell | 9,450 | $60.06 | $567,567.00 | 66,487 | |
| 1/4/2017 | Robert A Breyer | Director | Sell | 4,000 | $60.00 | $240,000.00 | 11,156 | |
| 1/3/2017 | David Joseph Gaffin | SVP | Sell | 2,500 | $55.40 | $138,500.00 | 27,207 | |
| 1/3/2017 | Paul J Mitchell | Director | Sell | 1,500 | $55.40 | $83,100.00 | 9,500 | |
| 12/16/2016 | Gordon G Pugh | COO | Sell | 21,458 | $57.65 | $1,237,053.70 | 37,277 | |
| 12/15/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $55.99 | $279,950.00 | 57,640 | |
| 12/14/2016 | James M Frates | SVP | Sell | 25,000 | $54.73 | $1,368,250.00 | 127,342 | |
| 12/12/2016 | Elliot Ehrich | CMO | Sell | 16,983 | $55.15 | $936,612.45 | 64,623 | |
| 12/8/2016 | Kathryn L Biberstein | CAO | Sell | 14,145 | $56.13 | $793,958.85 | 43,687 | |
| 12/7/2016 | James M. Frates | SVP | Sell | 23,731 | $56.28 | $1,335,580.68 | | |
| 12/1/2016 | Kathryn L Biberstein | CAO | Sell | 15,000 | $56.13 | $841,950.00 | 38,687 | |
| 11/30/2016 | Michael J Landine | SVP | Sell | 10,000 | $57.51 | $575,100.00 | 165,659 | |
| 11/29/2016 | Richard F Pops | Director | Sell | 30,000 | $56.98 | $1,709,400.00 | 638,962 | |
| 11/22/2016 | Richard F Pops | Director | Sell | 30,000 | $58.66 | $1,759,800.00 | 638,962 | |
| 10/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $47.42 | $94,840.00 | 10,000 | |
| 9/22/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $50.83 | $254,150.00 | 46,477 | |
| 9/16/2016 | Elliot Ehrich | CMO | Sell | 5,000 | $48.87 | $244,350.00 | 50,311 | |
| 9/6/2016 | David Joseph Gaffin | SVP | Sell | 2,382 | $45.92 | $109,381.44 | 22,816 | |
| 9/6/2016 | Elliot Ehrich | CMO | Sell | 10,000 | $46.02 | $460,200.00 | 55,311 | |
| 9/6/2016 | Iain Michael Brown | CAO | Sell | 29,976 | $45.92 | $1,376,497.92 | 25,696 | |
| 9/6/2016 | Paul J Mitchell | Director | Sell | 2,000 | $45.92 | $91,840.00 | 10,000 | |
| 8/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $49.48 | $98,960.00 | 10,000 | |
| 7/27/2016 | Elliot Ehrich | CMO | Sell | 35,199 | $51.95 | $1,828,588.05 | 46,111 | |
| 7/5/2016 | Paul J Mitchell | Director | Sell | 2,000 | $45.81 | $91,620.00 | 10,000 | |
| 6/6/2016 | Paul J Mitchell | Director | Sell | 2,000 | $44.98 | $89,960.00 | 10,000 | |
| 5/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $38.60 | $77,200.00 | 10,000 | |
| 4/20/2016 | Michael J Landine | SVP | Sell | 16,875 | $41.09 | $693,393.75 | 159,419 | |
| 4/19/2016 | Richard F Pops | CEO | Sell | 18,750 | $40.15 | $752,812.50 | 595,247 | |
| 4/18/2016 | Iain Michael Brown | CAO | Sell | 5,368 | $39.27 | $210,801.36 | 51,822 | |
| 4/13/2016 | Elliot Ehrich | CMO | Sell | 11,698 | $37.66 | $440,546.68 | 52,642 | |
| 4/12/2016 | Richard F Pops | CEO | Sell | 25,000 | $37.79 | $944,750.00 | 601,497 | |
| 4/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $35.65 | $71,300.00 | 10,000 | |
| 3/22/2016 | Richard F Pops | CEO | Sell | 25,000 | $31.77 | $794,250.00 | 601,497 | |
| 3/15/2016 | Richard F Pops | CEO | Sell | 25,000 | $31.40 | $785,000.00 | 581,307 | |
| 3/4/2016 | Paul J Mitchell | Director | Sell | 2,000 | $32.80 | $65,600.00 | 10,000 | |
| 3/3/2016 | David W Anstice | Director | Buy | 5,000 | $32.87 | $164,350.00 | 15,000 | |
| 2/4/2016 | Paul J. Mitchell | Director | Sell | 2,000 | $32.81 | $65,620.00 | 8,000 | |
| 1/4/2016 | Robert A Breyer | Director | Sell | 2,000 | $77.33 | $154,660.00 | 35,156 | |
| 12/28/2015 | Mark Stejbach | insider | Sell | 10,000 | $80.24 | $802,400.00 | 19,564 | |
| 12/23/2015 | Shane Cooke | insider | Sell | 18,000 | $77.23 | $1,390,140.00 | 50,240 | |
| 12/7/2015 | Michael J. Landine | SVP | Sell | 3,750 | $73.02 | $273,825.00 | 141,324 | |
| 12/7/2015 | Richard F. Pops | CEO | Sell | 37,500 | $72.06 | $2,702,250.00 | 553,497 | |
| 12/1/2015 | Mark Stejbach | insider | Sell | 18,000 | $72.18 | $1,299,240.00 | 19,564 | |
| 12/1/2015 | Michael J. Landine | SVP | Sell | 10,000 | $72.18 | $721,800.00 | 141,324 | |
| 12/1/2015 | Richard F. Pops | CEO | Sell | 50,000 | $72.29 | $3,614,500.00 | 553,497 | |
| 12/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $73.46 | $146,920.00 | 37,156 | |
| 11/23/2015 | Shane Cooke | insider | Sell | 18,000 | $72.62 | $1,307,160.00 | 50,240 | |
| 11/2/2015 | Mark Stejbach | insider | Sell | 18,000 | $72.06 | $1,297,080.00 | 19,964 | |
| 11/2/2015 | Robert A Breyer | Director | Sell | 2,000 | $71.80 | $143,600.00 | 39,156 | |
| 10/29/2015 | Iain Michael Brown | CAO | Sell | 10,822 | $69.99 | $757,431.78 | 38,689 | |
| 10/23/2015 | Shane Cooke | insider | Sell | 18,000 | $62.03 | $1,116,540.00 | 50,240 | |
| 10/13/2015 | James M. Frates | CFO | Sell | 20,000 | $59.78 | $1,195,600.00 | 51,357 | |
| 10/2/2015 | Robert A. Breyer | Director | Sell | 2,000 | $60.00 | $120,000.00 | 41,156 | |
| 9/23/2015 | Shane Cooke | insider | Sell | 18,000 | $67.09 | $1,207,620.00 | 40,640 | |
| 9/17/2015 | Michael J. Landine | SVP | Sell | 10,000 | $71.20 | $712,000.00 | 138,680 | |
| 9/17/2015 | Richard F. Pops | CEO | Sell | 50,000 | $71.27 | $3,563,500.00 | 542,917 | |
| 9/15/2015 | James M. Frates | CFO | Sell | 20,000 | $71.10 | $1,422,000.00 | 48,713 | |
| 9/10/2015 | Michael J. Landine | SVP | Sell | 10,000 | $67.61 | $676,100.00 | 138,680 | |
| 9/10/2015 | Richard F. Pops | CEO | Sell | 50,000 | $67.57 | $3,378,500.00 | 542,917 | |
| 9/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $61.43 | $122,860.00 | 43,156 | |
| 8/24/2015 | Shane Cooke | insider | Sell | 18,000 | $57.65 | $1,037,700.00 | 40,640 | |
| 7/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $69.79 | $1,256,220.00 | | |
| 7/20/2015 | Gordon G Pugh | COO | Sell | 18,750 | $70.10 | $1,314,375.00 | | |
| 7/14/2015 | James M Frates | CFO | Sell | 20,000 | $65.79 | $1,315,800.00 | | |
| 7/1/2015 | Gordon G Pugh | COO | Sell | 13,750 | $65.13 | $895,537.50 | | |
| 7/1/2015 | Robert A Breyer | Director | Sell | 2,000 | $64.90 | $129,800.00 | | |
| 6/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $66.84 | $1,203,120.00 | | |
| 6/17/2015 | Paul J Mitchell | Director | Sell | 15,500 | $65.10 | $1,009,050.00 | | |
| 6/16/2015 | Gordon G Pugh | COO | Sell | 32,977 | $63.11 | $2,081,178.47 | | |
| 6/16/2015 | James M Frates | CFO | Sell | 10,000 | $58.63 | $586,300.00 | | |
| 6/1/2015 | Paul J Mitchell | Director | Sell | 1,500 | $60.78 | $91,170.00 | | |
| 6/1/2015 | Rebecca Peterson | SVP | Sell | 21,983 | $60.05 | $1,320,079.15 | | |
| 5/26/2015 | Rebecca Peterson | SVP | Sell | 1,322 | $60.49 | $79,967.78 | | |
| 5/26/2015 | Shane Cooke | Insider | Sell | 18,000 | $60.31 | $1,085,580.00 | | |
| 5/22/2015 | Rebecca Peterson | SVP | Sell | 28,558 | $61.71 | $1,762,314.18 | | |
| 5/12/2015 | James M Frates | CFO | Sell | 10,000 | $59.34 | $593,400.00 | | |
| 5/4/2015 | Robert A Breyer | Director | Sell | 2,000 | $60.00 | $120,000.00 | | |
| 5/1/2015 | Paul J Mitchell | Director | Sell | 1,500 | $55.79 | $83,685.00 | | |
| 4/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $62.55 | $1,125,900.00 | | |
| 4/21/2015 | Elliot Ehrich | CMO | Sell | 25,000 | $62.39 | $1,559,750.00 | | |
| 4/15/2015 | Gordon G Pugh | COO | Sell | 13,750 | $63.21 | $869,137.50 | | |
| 4/15/2015 | James M Frates | CFO | Sell | 10,000 | $62.42 | $624,200.00 | | |
| 4/15/2015 | Paul J Mitchell | Director | Sell | 1,500 | $62.71 | $94,065.00 | | |
| 4/1/2015 | Robert A Breyer | Director | Sell | 5,000 | $61.22 | $306,100.00 | | |
| 3/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $65.33 | $1,175,940.00 | | |
| 3/16/2015 | Elliot Ehrich | CMO | Sell | 18,000 | $66.81 | $1,202,580.00 | | |
| 3/10/2015 | James M Frates | CFO | Sell | 10,000 | $66.25 | $662,500.00 | | |
| 3/5/2015 | Rebecca Peterson | SVP | Sell | 17,737 | $71.37 | $1,265,889.69 | | |
| 3/2/2015 | Gordon G Pugh | COO | Sell | 15,000 | $71.39 | $1,070,850.00 | | |
| 3/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $70.86 | $354,300.00 | | |
| 2/23/2015 | Shane Cooke | Insider | Sell | 18,000 | $74.29 | $1,337,220.00 | | |
| 2/17/2015 | Elliot Ehrich | CMO | Sell | 18,000 | $70.87 | $1,275,660.00 | | |
| 2/3/2015 | James M Frates | CFO | Sell | 10,000 | $70.83 | $708,300.00 | | |
| 2/2/2015 | Gordon G Pugh | COO | Sell | 15,000 | $72.01 | $1,080,150.00 | | |
| 2/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $72.91 | $364,550.00 | | |
| 1/26/2015 | Gordon G Pugh | COO | Sell | 15,000 | $70.02 | $1,050,300.00 | | |
| 1/23/2015 | Shane Cooke | Insider | Sell | 118,000 | $69.13 | $8,157,340.00 | | |
| 1/16/2015 | Floyd E Bloom | Director | Sell | 20,000 | $67.12 | $1,342,400.00 | | |
| 1/15/2015 | Elliot Ehrich | CMO | Sell | 18,375 | $66.45 | $1,221,018.75 | | |
| 1/15/2015 | James M Frates | CFO | Sell | 10,000 | $66.86 | $668,600.00 | | |
| 1/7/2015 | Kathryn L Biberstein | SVP | Sell | 28,374 | $65.00 | $1,844,310.00 | | |
| 1/2/2015 | Robert A Breyer | Director | Sell | 5,000 | $58.57 | $292,850.00 | | |
| 12/11/2014 | Richard F Pops | CEO | Sell | 100,000 | $56.04 | $5,604,000.00 | | |
| 12/10/2014 | James M Frates | CFO | Sell | 18,870 | $56.07 | $1,058,040.90 | | |
| 12/9/2014 | Michael J Landine | SVP | Sell | 18,000 | $56.82 | $1,022,760.00 | | |
| 12/5/2014 | Kathryn L Biberstein | SVP | Sell | 15,433 | $57.61 | $889,095.13 | | |
| 12/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $54.64 | $273,200.00 | | |
| 11/19/2014 | James M Frates | CFO | Sell | 8,000 | $53.86 | $430,880.00 | | |
| 11/13/2014 | Richard F Pops | CEO | Sell | 100,000 | $52.87 | $5,287,000.00 | | |
| 11/7/2014 | James M Frates | CFO | Sell | 13,303 | $49.98 | $664,883.94 | | |
| 11/6/2014 | Kathryn L Biberstein | SVP | Sell | 20,000 | $50.54 | $1,010,800.00 | | |
| 11/3/2014 | Robert A Breyer | Director | Sell | 5,000 | $50.05 | $250,250.00 | | |
| 10/23/2014 | Gordon G Pugh | COO | Sell | 14,577 | $45.00 | $655,965.00 | | |
| 10/8/2014 | James M Frates | CFO | Sell | 16,000 | $41.00 | $656,000.00 | | |
| 10/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $42.59 | $212,950.00 | | |
| 9/24/2014 | James M Frates | CFO | Sell | 16,000 | $45.29 | $724,640.00 | | |
| 9/18/2014 | Michael J Landine | SVP | Sell | 15,000 | $45.60 | $684,000.00 | | |
| 9/17/2014 | Gordon G Pugh | COO | Sell | 14,900 | $45.04 | $671,096.00 | | |
| 9/17/2014 | Richard F Pops | CEO | Sell | 50,000 | $44.89 | $2,244,500.00 | | |
| 9/10/2014 | James M Frates | CFO | Sell | 16,000 | $43.18 | $690,880.00 | | |
| 9/2/2014 | Gordon G Pugh | COO | Sell | 1,100 | $45.08 | $49,588.00 | | |
| 9/2/2014 | Robert A Breyer | Director | Sell | 5,000 | $45.12 | $225,600.00 | | |
| 8/27/2014 | James M Frates | CFO | Sell | 16,000 | $45.08 | $721,280.00 | | |
| 8/26/2014 | Gordon G Pugh | COO | Sell | 16,000 | $45.00 | $720,000.00 | | |
| 8/13/2014 | James M Frates | CFO | Sell | 15,000 | $41.37 | $620,550.00 | | |
| 8/11/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $41.65 | $694,180.55 | | |
| 8/4/2014 | Gordon G Pugh | COO | Sell | 23,250 | $43.20 | $1,004,400.00 | | |
| 8/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $42.53 | $212,650.00 | | |
| 7/16/2014 | James M Frates | CFO | Sell | 8,000 | $46.50 | $372,000.00 | | |
| 7/9/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $47.41 | $790,182.47 | | |
| 7/9/2014 | James M Frates | CFO | Sell | 7,000 | $47.41 | $331,870.00 | | |
| 7/3/2014 | Michael J Landine | SVP | Sell | 7,000 | $51.31 | $359,170.00 | | |
| 7/2/2014 | Richard F Pops | CEO | Sell | 50,000 | $51.69 | $2,584,500.00 | | |
| 7/1/2014 | Gordon G Pugh | COO | Sell | 16,000 | $46.49 | $743,840.00 | | |
| 7/1/2014 | Robert A Breyer | Director | Sell | 5,000 | $50.57 | $252,850.00 | | |
| 6/26/2014 | Michael J Landine | SVP | Sell | 10,000 | $49.92 | $499,200.00 | | |
| 6/25/2014 | James M Frates | CFO | Sell | 7,000 | $50.22 | $351,540.00 | | |
| 6/25/2014 | Richard F Pops | CEO | Sell | 50,000 | $49.87 | $2,493,500.00 | | |
| 6/20/2014 | Paul J Mitchell | Director | Sell | 17,000 | $50.00 | $850,000.00 | | |
| 6/19/2014 | Elliot Ehrich | CMO | Sell | 17,282 | $47.10 | $813,982.20 | | |
| 6/19/2014 | Michael J Landine | SVP | Sell | 10,000 | $47.01 | $470,100.00 | | |
| 6/18/2014 | Richard F Pops | CEO | Sell | 50,000 | $46.72 | $2,336,000.00 | | |
| 6/17/2014 | Kathryn L Biberstein | SVP | Sell | 8,400 | $47.41 | $398,244.00 | | |
| 6/11/2014 | James M Frates | CFO | Sell | 7,000 | $47.72 | $334,040.00 | | |
| 6/9/2014 | Elliot Ehrich | CMO | Sell | 16,667 | $48.15 | $802,516.05 | | |
| 6/2/2014 | Gordon G Pugh | COO | Sell | 16,000 | $45.34 | $725,440.00 | | |
| 6/2/2014 | Robert A Breyer | Director | Sell | 5,000 | $45.18 | $225,900.00 | | |
| 5/30/2014 | Rebecca Peterson | SVP | Sell | 21,981 | $45.86 | $1,008,048.66 | | |
| 5/23/2014 | Rebecca Peterson | SVP | Sell | 1,321 | $45.08 | $59,550.68 | | |
| 5/22/2014 | Elliot Ehrich | CMO | Sell | 2,378 | $44.49 | $105,797.22 | 20,992 | |
| 5/22/2014 | Gordon Pugh | COO | Sell | 15,700 | $45.25 | $710,425.00 | 54,192 | |
| 5/22/2014 | Rebecca Peterson | SVP | Sell | 19,807 | $44.02 | $871,904.14 | 1,321 | |
| 5/21/2014 | Elliot Ehrich | CMO | Sell | 1,981 | $44.00 | $87,164.00 | 23,370 | |
| 5/21/2014 | James Frates | CFO | Sell | 7,000 | $44.30 | $310,100.00 | 42,904 | |
| 5/20/2014 | Rebecca Peterson | SVP | Sell | 20,307 | $44.05 | $894,523.35 | | |
| 5/19/2014 | Elliot Ehrich | CMO | Sell | 2,206 | $43.55 | $96,071.30 | 20,992 | |
| 5/8/2014 | Floyd Bloom | Director | Sell | 10,000 | $46.16 | $461,600.00 | 90,281 | |
| 5/5/2014 | Robert Breyer | Director | Sell | 5,000 | $46.72 | $233,600.00 | 53,756 | |
| 5/1/2014 | Paul Mitchell | Director | Sell | 1,000 | $45.90 | $45,900.00 | 8,000 | |
| 4/9/2014 | James Frates | CFO | Sell | 7,000 | $42.91 | $300,370.00 | 36,644 | |
| 4/1/2014 | Paul Mitchell | Director | Sell | 1,500 | $44.14 | $66,210.00 | 8,000 | |
| 3/19/2014 | James Frates | CFO | Sell | 7,000 | $46.84 | $327,880.00 | 36,644 | |
| 3/11/2014 | Wendy Dixon | Director | Buy | 1,600 | $47.37 | $75,792.00 | 1,600 | |
| 3/5/2014 | James Frates | CFO | Sell | 7,000 | $47.78 | $334,460.00 | 93,644 | |
| 2/18/2014 | Elliot Ehrich | CMO | Sell | 7,718 | $52.45 | $404,809.10 | 16,579 | |
| 2/3/2014 | Paul Mitchell | Director | Sell | 1,500 | $48.15 | $72,225.00 | 8,000 | |
| 1/21/2014 | Elliot Ehrich | CMO | Sell | 7,718 | $48.61 | $375,171.98 | 16,579 | |
| 1/16/2014 | Elliot Ehrich | CMO | Sell | 14,555 | $47.35 | $689,179.25 | 16,579 | |
| 1/16/2014 | Gordon Pugh | COO | Sell | 30,000 | $47.16 | $1,414,800.00 | 48,301 | |
| 1/16/2014 | James Frates | CFO | Sell | 7,000 | $47.40 | $331,800.00 | 93,644 | |
(Data available from 1/1/2013 forward)
Alkermes (NASDAQ ALKS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical ...
www.prnewswire.com - May 23 at 8:57 AM |
 | Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
finance.yahoo.com - May 23 at 8:57 AM |
 | Analysts Expect Alkermes Plc (ALKS) Will Announce Quarterly Sales of $251.99 Million
www.americanbankingnews.com - May 21 at 3:06 AM |
| Zacks: Analysts Expect Alkermes (ALKS) to Announce $0.03 Earnings Per Share
www.americanbankingnews.com - May 19 at 1:25 PM |
 | Form 4 Alkermes plc. For: May 17 Filed by: LANDINE MICHAEL J
www.streetinsider.com - May 19 at 9:00 AM |
| Michael J. Landine Sells 20,000 Shares of Alkermes (ALKS) Stock
www.americanbankingnews.com - May 17 at 7:37 PM |
| Alkermes (ALKS) CEO Sells $2,319,000.00 in Stock
www.americanbankingnews.com - May 17 at 7:35 PM |
| Alkermes (ALKS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 16 at 4:51 PM |
| Citi Upgrades Alkermes (ALKS) to Buy
www.streetinsider.com - May 16 at 4:46 PM |
| Alkermes (ALKS) Rating Increased to Buy at Citigroup
www.americanbankingnews.com - May 16 at 3:21 PM |
| Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference
finance.yahoo.com - May 14 at 4:45 PM |
| Alkermes (ALKS) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 14 at 10:15 AM |
| Alkermes (ALKS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - May 12 at 5:01 PM |
| Alkermes (ALKS) August volatility flat into primary endpoints for ENLIGHTEN-2
www.streetinsider.com - May 11 at 4:50 PM |
| Alkermes (ALKS) Research Coverage Started at Bank of America
www.americanbankingnews.com - May 11 at 3:56 PM |
| Richard F. Pops Sells 50,000 Shares of Alkermes (ALKS) Stock
www.americanbankingnews.com - May 10 at 7:19 PM |
| Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference
finance.yahoo.com - May 10 at 4:56 PM |
| Form SC 13G/A Alkermes plc. Filed by: PRIMECAP MANAGEMENT CO/CA/
www.streetinsider.com - May 8 at 4:45 PM |
| Alkermes (ALKS) Cut to Sell at BidaskClub
www.americanbankingnews.com - May 8 at 11:02 AM |
| Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research
www.prnewswire.com - May 4 at 7:30 AM |
| Pre-Market Technical Scan on Drug Delivery Equities -- Adamis Pharma, Alkermes, PetMed Express, and Valeant Pharma
www.prnewswire.com - May 4 at 7:30 AM |
| Brokerages Expect Alkermes (ALKS) Will Announce Quarterly Sales of $251.99 Million
www.americanbankingnews.com - May 4 at 4:54 AM |
| Alkermes (ALKS) Downgraded by ValuEngine
www.americanbankingnews.com - May 3 at 11:47 PM |
| Alkermes (ALKS) Director Richard F. Pops Sells 50,000 Shares
www.americanbankingnews.com - May 3 at 7:33 PM |
| Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program
finance.yahoo.com - May 3 at 4:39 PM |
| Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 4:47 PM |
| $0.11 EPS Expected for Alkermes (ALKS) This Quarter
www.americanbankingnews.com - May 2 at 1:24 AM |
| Alkermes (ALKS) Downgraded to D+ at TheStreet
www.americanbankingnews.com - May 1 at 8:38 AM |
| Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting
finance.yahoo.com - April 30 at 9:18 AM |
| Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1
finance.yahoo.com - April 29 at 9:25 AM |
| Credit Suisse Group Reiterates "$57.00" Price Target for Alkermes (ALKS)
www.americanbankingnews.com - April 28 at 9:14 AM |
 | Alkermes (ALKS) Q1 2018 Earnings Conference Call Transcript
www.fool.com - April 27 at 1:42 PM |
| Alkermes (ALKS) Issues Quarterly Earnings Results
www.americanbankingnews.com - April 26 at 5:52 PM |
| Alkermes Plc Reports First Quarter 2018 Financial Results
www.prnewswire.com - April 26 at 4:41 PM |
| What Are Analysts Saying About Alkermes plc’s (NASDAQ:ALKS) Earnings Outlook?
finance.yahoo.com - April 26 at 4:41 PM |
| After a Bumpy Ride, Alkermes Confirms That It's Back on Track
finance.yahoo.com - April 26 at 4:41 PM |
| After a Bumpy Ride, Alkermes Confirms That It's Back on Track
www.fool.com - April 26 at 3:34 PM |
| Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia
www.prnewswire.com - April 26 at 8:59 AM |
 | BRIEF-Alkermes Q1 GAAP Loss Per Share $0.40
www.reuters.com - April 26 at 8:59 AM |
| Alkermes: 1Q Earnings Snapshot
finance.yahoo.com - April 26 at 8:59 AM |
| Alkermes (ALKS) option implied volatility elevated into EPS and outlook
www.streetinsider.com - April 25 at 4:50 PM |
 | Alkermes' ALKS 5461 Moves Closer To Commercialization
seekingalpha.com - April 24 at 4:55 PM |
| Is Alkermes' Promising Depression Drug Back On Track?
www.fool.com - April 24 at 9:06 AM |
| Is Alkermes' Promising Depression Drug Back On Track?
finance.yahoo.com - April 23 at 4:38 PM |
| Johnson & Johnson's First-Quarter 2018 Earnings Review
finance.yahoo.com - April 22 at 5:37 PM |
| Alkermes (ALKS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:52 AM |
| Alkermes Gets Ability To Refile NDA, But All Is Still Not Rosy
seekingalpha.com - April 19 at 4:52 PM |
| Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results
finance.yahoo.com - April 19 at 4:52 PM |
| Alkermes Plc (ALKS) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 19 at 10:15 AM |
| Alkermes (ALKS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM |
Alkermes (NASDAQ:ALKS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alkermes (NASDAQ:ALKS) Income Statement, Balance Sheet and Cash Flow Statement
Alkermes (NASDAQ ALKS) Stock Chart for Thursday, May, 24, 2018
Loading chart…
